Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Exploratory Study of Golidocitinib in Adult Patients With ITP
Sponsor: Peking University People's Hospital
Summary
This is a multicenter clinical study to evaluate the safety and efficacy of golidocitinib in patients with primary immune thrombocytopenia (ITP). The study consists of two parts: Part A dose escalation and Part B dose expansion. Part A is designed to obtain the safety profile of golidocitinib in patients with ITP and the recommended dose for the randomized cohort in Part B. Part B is a randomized, double-blind, placebo-controlled study, and the primary objective of this part is to evaluate the preliminary efficacy of golidocitinib in patients with ITP.
Official title: An Exploratory Clinical Study of Golidocitinib in Adult Patients With Primary Immune Thrombocytopenia (ITP)
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
138
Start Date
2025-10-30
Completion Date
2029-10-30
Last Updated
2025-09-29
Healthy Volunteers
No
Conditions
Interventions
Golidocitinib
Golidocitinib will be administered orally as capsules in a 28-day cycle.
Placebo
Placebo will be administered orally as capsules in a 28-day cycle.
Locations (1)
Peking University Insititute of Hematology, Peking University People's Hospital
Beijing, Beijing Municipality, China